Wegovy & Ozempic Shortage Over: Supply Stabilizes and FDA Moves to Limit Compounded Alternatives.
GLP-1 Availability Shifts: FDA Actions Impact Compounded Wegovy and Ozempic After Removal From Drug Shortage List February 21, 2025 - The landscape of GLP-1 medication availability is undergoing significant changes, with the U.S. Food and Drug Administration (FDA) announcing the resolution of shortages for key drugs like semaglutide (Wegovy and Ozempic) and tirzepatide (Zepbound and Mounjaro). These decisions have major implications for compounding pharmacies and patient access to these popular weight-loss and diabetes medications. Patients who rely on affordable medication from reputable compounding pharmacies may now be required to purchase the brand named GLP-1 medications at a considerably higher cost which may make them unaffordable to many of the same people who rely on them Semaglutide Shortage Resolved, Compounding Restrictions Imminent: The FDA has officially determined that the shortage of semaglutide injection products, including Wegovy and Ozempic, is re...